Particular subtypes of acute myeloid leukemia (AML)s and myelodysplastic syndromes (MDS) are associated with specific recurrent chromosomal anomalies. Among these are translocations involving 21q22, which are commonly observed in both de novo and therapy-related (t-)MDS and AML. The t(8;21)(q22;q22), t(3;21)(q26;q22) and t(16;21)(q24;q22) are most frequently observed, but other variants have been described as well. 1, 2 The majority of these translocations result in a fusion of the 5 0 region of the RUNX1 (CBFA2, AML1) gene with the 3 0 region of either one of its partner genes. 1 Here, we report a patient with therapy-related AML and a rare t(1;21)(p36;q22). 3 0 RACE experiments followed by sequencespecific RT-PCR resulted in the identification of the PRDM16 gene as a novel fusion partner of the RUNX1 gene in this patient.
A 47-year-old woman was referred to our hospital with pancytopenia in 2002. In 1999, she had been diagnosed elsewhere with invasive breast cancer and positive axillary lymph nodes without distant metastases, for which she was treated with mastectomy, adjuvant radiotherapy, chemotherapy and tamoxifen. Hematologic examination showed white blood cells (WBC) of 1.1 Â 10 9 /l with 43% polymorphonuclear cells (PMN's), hemoglobin level of 7.0 mmol/l and a platelet count of 42 Â 10 9 /l. Bone marrow biopsy showed hypoplastic bone marrow with severe myelodysplasia. Bone marrow karyotypes were obtained after short-term cultures, chromosomes were GTG-banded and the karyotype was described according to the International System for Human Cytogenetic Nomenclature (Figure 1, right panel) . As normal female karyotype was found at diagnosis, these chromosomes were evaluated. Owing to the lack of quality of the metaphases and lack of suitable material for FISH analysis, we cannot exclude the possibility that the cryptic translocation t(1;21)(p36;q22) was missed at diagnosis. In July 2005, bone marrow examination revealed an acute myelomonocytic leukemia and a 46,XX,t(1;21)(p36;q22),del(7)(q?34) [7] /47,idem, þ 13 [3] karyotype. The patient died a few months later. An extensive literature search through Medline (http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi) and the Mittelman Database of Chromosome Aberrations in Cancer (http://cgap.nci.nih.gov/Chromosomes/Mitelman) revealed four additional cases (Table 1 ). This turns the t(1;21)(p36;q22) into a rare but recurrent translocation. The t(1;21)(p36;q22) seems to be associated with a relatively short survival time (6-7 months). (Partial) loss of chromosome 7 was observed in case 2 and in the present case during relapse. Although only present in two cases, it should be noted that chromosome 7 abnormalities are the most commonly observed secondary changes in patients with other 21q22 translocations. 1 Two cases were therapy-related and had treatment histories that included topoisomerase II targeting agents. This observation Letters to the Editor provides further evidence for the previously observed association between RUNX1 translocations and treatment with topoisomerase II inhibitors. 2 Aiming at the identification of a presumed chromosome 1p36 fusion gene, we performed RUNX1-primed 3 0 Rapid Amplification of cDNA Ends (RACE) analysis. Total RNA was extracted from a bone marrow aspirate (April 2005) using a RNA-beebased protocol following the instructions of the manufacturer (Bioconnect, Huissen, The Netherlands). cDNA synthesis was performed in two parallel reactions using both random hexamers and universal adaptor primer 2 (UAP2)-tailed T(17), in combination with Superscript III reverse transcriptase (Invitrogen). The following 3 0 RACE-primers were subsequently used: GAGCCCAGGCAAGATGAG (first round PCR, RUNX1 exon 3-specific primer), CTACCGCAGCCATGAAGAAC (second round, RUNX1 exon 4-specific primer), both in combination with universal adaptor primer UAP2. Agarose gel electrophoresis revealed several distinct PCR products (data not shown), which were all excised from gel, cloned and sequenced. Two of the products were composed of RUNX1 sequences (comprising exons 4 (partially), 5 and 6) fused to sequences, which were found to be residing within intron 1 of the PRDM16 gene (Figure 2) . The presumed cryptic, PRDM16-related exon adds 59 residues to a carboxy-terminal truncated RUNX1 protein. A Pfam search at http://www.sanger.ac.uk/ Software/Pfam/ did not reveal any protein domains encoded by these added residues, and a blastp-search at http:// www.ncbi.nlm.nih.gov/BLAST/ failed to detect any significant homology to any known protein. From these findings we conclude that the intron 1-derived sequences are not likely to result in the addition of any functional protein domain(s), but rather provide a poly-adenylation function to a fraction of the 3 0 -truncated RUNX1 transcripts, thereby stabilizing the truncated RUNX1 transcripts.
After identification of PRDM16 sequences, a more sensitive and specific RT-PCR strategy was applied on a mixture of UAP2 and random-primed cDNA, using various combinations of RUNX1 and PRDM16-specific primers including CTACCG Schematic representation of RUNX1 and PRDM16 (fusion) genes. Upper panel: normal genomic structures of PRDM16 (coding exons indicated in green, noncoding parts in blue), and RUNX1 (coding exons indicated in red, noncoding parts in blue). A cryptic exon, residing within intron 1 of PRDM16, which was identified by 3 0 RACE analysis, is indicated in green (speckled). Lower panel: structure of RUNX1-PRDM16 fusion transcripts. Please note that the cryptic PRDM16 exon (present in the fusion gene) is not present in the spliced fusion transcript detected by RT-PCR analysis. Positions of gene-specific primers used for 3 0 RACE and/or RT-PCR analysis are indicated by triangles. Exons are numbered on the basis of consensus gene sequences. Exon sizes are not to scale. Letters to the Editor CAGCCATGAAGAAC (RUNX1 exon 4-specific forward primer) and CGTGTAGGACTTGTGGCAGA (PRDM16 exon 9-specific reversed primer). The results of this experiment confirmed (data not shown) the anticipated RUNX1-PRDM16 fusion transcripts composed of RUNX1 sequences upstream of exon 7, followed by PRDM16 sequences downstream of exon 1 (Figure 2) . No fragments resulting from alternative splicing or exon skipping were found among the PCR fragments analyzed. In addition, no reciprocal PRDM16-RUNX1 chimeras were identified, which might indicate that the RUNX1-PRDM16 fusion gene is the most relevant one for inducing leukemia. During the preparation of this manuscript, others independently identified the PRDM16 gene as novel fusion partner of RUNX1 in an AML patient with a t(1;21)(p36;q22) (case 4, Table 1 ). The PRDM16 gene encodes a zinc finger protein containing two DNA binding domains and a PRDI-BF1 (positive regulatory domain I binding factor 1)/RIZ (retinoblastoma-interacting zinc finger protein) homologous (PR) domain at the N-terminus. 6 The evolutionary conserved PR domain is highly homologous to the PR domain as encoded by MDS1/EVI1 gene. Furthermore, the DNA-binding consensus sequence of EVI1 overlaps with that of the PRDM16 protein, suggesting that PRDM16 has a similar DNA-binding capacity and transcriptional regulation activity as EVI1. Moreover, both genes are transcriptionaly activated by chromosome rearrangements involving the RPN1 gene at chromosome 3q21 in the t(1;3)(p36;q21) and inv(3)(q21q26)/ t(3;3)(q21;q26), 6 respectively, and both genes can form fusion genes with RUNX1.
RUNX1 is essential for hematopoiesis in the fetal liver and myeloid differentiation in adult bone marrow. The gene encodes the CBFa2 subunit of the core binding factor, a heterodimeric transcription factor complex composed of CBFa and CBFb. 2 The amino-terminus contains the DNA-binding runt domain, whereas at the carboxy-terminus a transactivation domain is present. As a result of the RUNX1-targeting translocations, the DNA-binding domain becomes separated from the transactivation domain, and is fused to sequences originating from the partner gene. The breakpoints in at least three (case 1, case 4 and present case) of the t(1;21)(p36;q22) patients are localized in intron 6, which is also the affected intron in most of the t(3;21)(q26;q22) patients, while in patients with a t(8;21)(q22;q22) the breakpoint is frequently found within intron 5.
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The RUNX1-PRDM16 fusion transcript identified by RACE-PCR contains the runt DNA binding domain, but lacks the transactivation domain of RUNX1, fused to sequences derived from intron 1 of PRDM16. The predicted RUNX1-PRDM16 chimeric protein contains a limited number of PRDM16 residues fused to RUNX1 in a similar manner to the t(3;21) related RUNX1-EAP and the recently reported RUNX1-PRDM16 fusion. 5 It is possible that, similar to RUNX1-EAP, 8 the truncated RUNX1 gene product may compete with wild-type RUNX1 and act as a dominant-negative inhibitor of the RUNX1 protein.
RT-PCR confirmed the presence of a RUNX1-PRDM16 rearrangement. In addition, a second, similar as recently described, 5 RUNX1-PRDM16 fusion transcript was identified which contains the almost entire PRDM16 coding sequence. As a result of this chimeric transcript the almost entire PRDM16 protein, which is normally absent in hematopoietic cells, will be expressed under the control of the active RUNX1 promoter. It is likely, that similar has been suggested for patients carrying a t(1;3)(p36;q21), that ectopic PRDM16 expression contributes to the pathogenesis of MDS and AML. 6 The RUNX1-PRDM16 gene shares extensive homology with RUNX1-MDS1/ EVI1. 6 Therefore, it is possible that the RUNX1-PRDM16 fusion protein plays a similar role in the leukemic process in a similar way as has previously been demonstrated for the RUNX1-MDS1/EVI1. 9 Although relatively rare, the t(1;21)(p36;q22) translocation represents a recurrent translocation targeting the RUNX1 and PRDM16 genes. At least three mechanisms through which the RUNX1-PRDM16 fusion might induce malignant transformation in hematopoietic cells are possible: expression of truncated RUNX1, expression of the RUNX1-PRDM16 fusion gene (both resulting in dominant negative inhibition of RUNX1), and ectopic PRDM16 expression. Identification of recurrent fusion genes will not only add to a better understanding of altered signaling mechanisms triggering oncogenesis, but also will enable specific molecular subtyping and, by doing so, facilitate therapeutic decision making. 
